Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Cory who wrote (31505)	2/29/2000 8:34:00 AM
From: Jesse James	Read Replies (2) \| Respond to of 150070

EMED...ISLD mm asking 4.75...eom

To: Cory who wrote (31505)	2/29/2000 9:01:00 AM
From: jpmac	Read Replies (1) \| Respond to of 150070

BICO news ~ biz.yahoo.com Biocontrol Technology, Inc. Subsidiary, IDT, Inc. and Capital Management Consulting, Inc. Form Strategic and Corporate Development Alliance PITTSBURGH, Feb. 29 /PRNewswire/ -- Biocontrol Technology, Inc. (OTC Bulletin Board: BICO - news) announced today that its subsidiary, IDT, Inc., has formed a strategic and corporate development alliance with Capital Management Consulting, Inc. (Capital) to position the Company for growth, development, and partnerships. Capital specializes in the design and implementation of value-creating strategy for the medical products industry. Located in Boston, MA, Capital's strategic development and advisory services have impacted portfolios, partnerships, and acquisitions with an aggregate value in excess of $10 billion. Joseph Kozikowski, M.D., who has extensive experience in designing and executing clinical development programs, product registrations, and strategic alliances, will lead Capital's IDT team. Dr. Kozikowski studied business at Harvard Business School, law at The Food and Drug Law Institute, and medicine at The Johns Hopkins University School of Medicine. Richard Morroney, who will provide regulatory affairs and product development expertise, has led numerous successful FDA submissions and has successfully developed and implemented medical product quality systems and strategies. Thong Q. Le, who will provide business and market development expertise, has extensive experience in strategic alliances, market analysis, and finance. Mr. Le studied business and economics at the Templeton College Graduate School of Business Administration of Oxford University and at Harvard University. In January 2000, IDT announced that, in conjunction with HemoCleanse, Inc., FDA clearance has been obtained to market the ThermoChem-HT(TM) System and related disposables with intended use to raise the core temperature of the peritoneum to the desired temperature in the 41 degrees C (105.8 degrees F) to 42 degrees C (107.6 degrees F) range by continuously bathing the peritoneum with circulating sterile solutions. The ThermoChem-HT System will now be available to help standardize a revolutionary cancer treatment of ovarian, gastrointestinal, and other tumors that have spread to the lining surface of the abdomen and pelvis. IDT, again in conjunction with HemoCleanse, Inc., also announced in mid-February 2000 that it has received FDA approval and Institutional Review Approval from the University of Texas Medical Branch at Galveston to continue a human clinical trial to treat patients with non-small cell lung cancer. Biocontrol Technology has its corporate offices in Pittsburgh, PA and is involved in the development and manufacture of biomedical devices and environmental products. IDT, Inc. a subsidiary of Biocontrol also located in Pittsburgh, PA, holds exclusive worldwide marketing rights to the ThermoChem-HT technology and related disposables for regional hyperthermia and ThermoChem technology and related disposables for whole body hyperthermia. WEBSITE: www.bico.com INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204 This press release contains statements of a forward-looking nature. Shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly. SOURCE: Biocontrol Technology, Inc.